Document is current
Any future updates will be listed below
-
Authors
Kawashima, Naomi https://orcid.org/0000-0002-9914-739X
Ishikawa, Yuichi https://orcid.org/0000-0001-6024-6617
Kim, Jeong Hui
Ushijima, Yoko
Akashi, Akimi
Yamaguchi, Yohei
Hattori, Hikaru
Nakashima, Marie
Ikeno, Seara
Kihara, Rika
Nishiyama, Takahiro
Morishita, Takanobu
Watamoto, Koichi
Ozawa, Yukiyasu
Kitamura, Kunio
Kiyoi, Hitoshi https://orcid.org/0000-0001-6382-9498
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (17ck0106251h0001, 18ck0106251h0002, 19ck0106251h0003, 20ck0106535h0001, 21ck0106535h0002, 19cm0106562h0001, 20cm0106562h0002, 21cm0106581h0001)
Ministry of Education, Culture, Sports, Science and Technology (17K09921)
- License Information
-
More Information
Article History
Received: 13 July 2020
Accepted: 2 March 2022
First Online: 25 March 2022
Competing interests
: H. Kiyoi received research funding from FUJIFILM Corporation, Kyowa Hakko Kirin Co., Ltd., Bristol-Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Perseus Proteomics Inc., Daiichi Sankyo Co., Ltd., Abbvie Inc., CURED Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Novartis Pharma K.K., Sanofi K.K., and Pfizer Japan Inc., and honoraria from Bristol-Myers Squibb, Astellas Pharma Inc., and Novartis Pharma K.K. The remaining authors declare no competing interests. All other authors have no competing non-financial interests to declare.
